Floatz logo

Binimetinib

Low-grade Glioma

National Cancer Center, JapanSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Low-grade Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 2B
Tazemetostat
National Cancer Institute (NCI)
Phase 2B
FET
Thomas Hope
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 14 →

Same molecule, other indications

Binimetinib is also rated in:

metastatic malignant neoplasm in the colonDormant
BB
Indicative ·
70 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
68 / 100
View asset →
triple-negative breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →